Trials / Not Yet Recruiting
Not Yet RecruitingNCT07007286
Real-world Study on Liver Cancer Risk in Chronic Hepatitis B Patients With Family History of Liver Cancer
A Real-World Study on Reducing the Risk of Liver Cancer in Chronic Hepatitis B Patients With a Family History of HBV-Related Liver Cancer.
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,500 (estimated)
- Sponsor
- Peking University First Hospital · Academic / Other
- Sex
- All
- Age
- 30 Years
- Healthy volunteers
- Not accepted
Summary
This study is a prospective, multicenter, real-world cohort study designed to compare the long-term outcomes of chronic hepatitis B patients with a family history of HBV-related hepatocellular carcinoma (HCC) who receive PEG IFNα-2b combined with nucleos(t)ide analogues or nucleos(t)ide monotherapy. The primary endpoint is the incidence rate of HCC, and secondary endpoints include the rate of HBsAg seroclearance, changes in liver fibrosis, and survival rates. The study will last for 5 years and enroll approximately 15,000 patients, aiming to provide evidence-based optimization for CHB treatment regimens.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ETV,TDF,TAF,TMF combination with PEG IFNα-2b | The study will not involve any additional interventions, nor will it interfere with any related clinical decision-making. |
| DRUG | ETV,TDF,TAF or TMF | The study will not involve any additional interventions, nor will it interfere with any related clinical decision-making. |
Timeline
- Start date
- 2025-06-01
- Primary completion
- 2032-01-01
- Completion
- 2032-12-01
- First posted
- 2025-06-05
- Last updated
- 2025-06-05
Locations
555 sites across 1 country: China
Source: ClinicalTrials.gov record NCT07007286. Inclusion in this directory is not an endorsement.